U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H34O10.K.Na
Molecular Weight 592.6516
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of POTASSIUM SODIUM 14-DEOXY-11,12-DEHYDROANDROGRAPHOLIDE SUCCINATE

SMILES

[Na+].[K+].[H][C@]12CCC(=C)[C@@H](\C=C\C3=CCOC3=O)[C@]1(C)CC[C@@H](OC(=O)CCC([O-])=O)[C@@]2(C)COC(=O)CCC([O-])=O

InChI

InChIKey=KYEPHZAHIRDQSR-SXASYTFBSA-L
InChI=1S/C28H36O10.K.Na/c1-17-4-7-20-27(2,19(17)6-5-18-13-15-36-26(18)35)14-12-21(38-25(34)11-9-23(31)32)28(20,3)16-37-24(33)10-8-22(29)30;;/h5-6,13,19-21H,1,4,7-12,14-16H2,2-3H3,(H,29,30)(H,31,32);;/q;2*+1/p-2/b6-5+;;/t19-,20+,21-,27+,28+;;/m1../s1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C28H34O10
Molecular Weight 530.5636
Charge -2
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 1
Optical Activity UNSPECIFIED

Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Dehydroandrographolide (DP) from Andrographis paniculata (Burm. F.) Nees is a potential anticancer agent which can act, in part, through the inhibition of TMEM16A expression and may support TMEM16A as a novel target for antitumor therapy in TMEM16A-amplified cancers. It was shown that DP inhibits the invasion of human oral cancer cells and is a potential chemopreventive agent against oral cancer metastasis. It is also used for the treatment of infections in China. However, DP has not been found to significantly inhibit bacterial and viral growth directly. It was discovered that the DP enhanced innate immunity of intestinal tract through increased expression of human β -defensin-2 (hBD-2) through the p38 MAPK pathways. Dehydroandrographolide also possesses activity against hepatitis B virus

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q5XXA6
Gene ID: 55107.0
Gene Symbol: ANO1
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Dehydroandrographolide succinic acid monoester as an inhibitor against the human immunodeficiency virus.
1991 May
Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: herb-drug interactions mediated via P-gp.
2014 Mar 1
Identification of the Novel TMEM16A Inhibitor Dehydroandrographolide and Its Anticancer Activity on SW620 Cells.
2015

Sample Use Guides

in mice: For experimental xenograft growth inhibition study, 5–6 week male BALB/c nude mice (18–22 g) were used. SAS cells (2 × 106 per mouse) were resuspended in 200 μl of sterile PBS and injected s.c. into the right flank of the mouse. Mice were randomized into two groups (5 mice/group). All animals were housed with a regular 12-h light/12-h dark cycle and water ad libitum access to standard rodent chow diet and kept in a pathogen-free environment at the Laboratory Animal Unit. Seven days after tumor cell injection, the mice were orally fed dehydroandrographolide (DA) (40 or 100 mg/kg) or vehicle three times per week.
Route of Administration: Oral
Human intestinal epithelial HCT-116 cells were incubated with 1-100 μM Dehydroandrographolide (DA) for 2-24 h. RT-PCR and Western blot were used to assess the expression of human β -defensin-2 (hBD-2). The specific inhibitors were used and the levels of phosphorylation of signaling molecules were detected for dissecting the signaling pathways leading to the induction of hBD-2. MTT assay showed there was no obvious cytotoxicity for HCT-116 cells by 1-100 μM DA treatment. RT-PCR and Western blot assays showed that DA (1-100 μM) could up-regulate the expression of hBD-2, and the effect lasted longer than 24 h.
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:46:13 GMT 2023
Edited
by admin
on Sat Dec 16 18:46:13 GMT 2023
Record UNII
4OCV4ALL6P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
POTASSIUM SODIUM 14-DEOXY-11,12-DEHYDROANDROGRAPHOLIDE SUCCINATE
Common Name English
14-DEOXY-11,12-DIDEHYDROANDROGRAPHOLIDE BIS(HEMISUCCINATE) POTASSIUM SODIUM SALT
Systematic Name English
YANHUNING
Common Name English
DEHYDROANDROGRAPHOLIDE SUCCINATE POTASSIUM SODIUM
Common Name English
Dehydroandrographolide succinate potassium sodium [WHO-DD]
Common Name English
BUTANEDIOIC ACID, 1-(((1R,2R,4AR,5R,8AS)-2-(3-CARBOXY-1-OXOPROPOXY)-5-((1E)-2-(2,5-DIHYDRO-2-OXO-3-FURANYL)ETHENYL)DECAHYDRO-1,4A-DIMETHYL-6-METHYLENE-1-NAPHTHALENYL)METHYL) ESTER, POTASSIUM SODIUM SALT (1:1:1)
Systematic Name English
POTASSIUM SODIUM DEHYDROANDROGRAPHOLIDE SUCCINATE
Common Name English
POTASSIUM SODIUM DEHYDROANDROANDROGRAPHOLIDE SUCCINATE
Common Name English
Code System Code Type Description
FDA UNII
4OCV4ALL6P
Created by admin on Sat Dec 16 18:46:13 GMT 2023 , Edited by admin on Sat Dec 16 18:46:13 GMT 2023
PRIMARY
CAS
863319-40-8
Created by admin on Sat Dec 16 18:46:13 GMT 2023 , Edited by admin on Sat Dec 16 18:46:13 GMT 2023
PRIMARY
PUBCHEM
73351134
Created by admin on Sat Dec 16 18:46:13 GMT 2023 , Edited by admin on Sat Dec 16 18:46:13 GMT 2023
PRIMARY
SMS_ID
100000174325
Created by admin on Sat Dec 16 18:46:13 GMT 2023 , Edited by admin on Sat Dec 16 18:46:13 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY